SITC Announces Mary Dean, JD, CAE, as its Executive Director
The Society for Immunotherapy of Cancer, the world’s leading membership-driven organization dedicated solely to cancer immunotherapy, is pleased to announce that Mary Dean, JD, CAE, has been named Executive Director of the association.
Ms. Dean steps into her new role after serving as the Associate Executive Director of SITC since February 2018, helping steward the strategic vision of the society as set forth by its members. She has more than 16 years of association experience. She spent the majority of those years serving as the Executive Director for the American Society of Gene & Cell Therapy, in addition to the Executive Director for the Society of Behavioral Medicine, American Venous Forum, and Growing Spine Foundation.
Please click here to read more about today's announcement.
Download Global Access Workshop Presentation Materials
- David Kaufman, MD, PhD – Third Rock Ventures
- Samir Khleif, MD – Georgetown University
SITC is pleased to make available presentation materials for the workshop, Global Access to Immunotherapy: Closing the Gaps. Hosted virtually on Dec. 9–10, 2020, the purpose of this workshop was to bring together immunotherapy experts from high-income countries (HIC) with experts on cancer delivery and research from low- and middle-income countries (LMIC) to define optimal approaches to a number of challenges.
Access to cancer immunotherapies, particularly PD-1 checkpoint blockade, is restricted in LMICs relative to HICs. Aside from health economic barriers, key issues that need to be addressed to facilitate access include
- Defining the minimal hospital, staff and pharmacy requirements for safe administration and monitoring of therapy
- Understanding how specific co-morbidities, environmental factors and local cancer epidemiology influence the safety and efficacy profile of cancer immunotherapy
- Understanding the regulatory and EC/IRB requirements to study and ultimately register novel immunotherapies in LMIC, and
- Determining the most impactful approaches to provider and community education.
Please click here to learn more about this workshop and to begin accessing the enduring materials.
Virtually Attend the 2020 SITC Cancer Immunotherapy Winter School
SITC is pleased to host its third annual Cancer Immunotherapy Winter School, a comprehensive cancer immunotherapy education program, which will be held virtually on Feb. 22–24, 2021. Taught by leading experts in the field, this program provides a deep understanding of the core principles of tumor immunology and cancer immunotherapy as well as developing areas in the field including biomarker technology, validation and clinical integration; clinical trial design, data analysis and considerations for combination therapies.
Winter School Organizers:
- Christian Capitini, MD – University of Wisconsin-Madison
- Leisha A. Emens, MD, PhD – UPMC Hillman Cancer Center
- Daniel Powell, PhD – University of Pennsylvania
The Cancer Immunotherapy Winter School program is tailored to early-to-mid career scientists and clinicians in the field of cancer immunotherapy working in academic, clinical, industry and government settings as well as those new to the field. The curriculum covers the fundamentals of cancer immunotherapy and features separate tracks, including clinical and research, allowing participants to tailor their experience by selecting the educational path most relevant to their learning goals.
Click here to view registration rates for this program and then register now to confirm your attendance.